New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
15:53 EDTAGN, TEVA, NVSAppeals court upholds judgment in favor of Allergan in suit with Teva, Sandoz
The U.S. Appeals Court for the Federal Circuit affirmed a lower court ruling that proposed products described in Abbreviated New Drug Applications from Teva Pharmaceuticals (TEVA) and Sandoz, a unit of Novartis (NVS), infringed claim 10 of Allergan's (AGN) 819 patent for Lumigan. Lumigan is FDA approved to reduce intraocular pressure in people with ocular hypertension or glaucoma. Reference Link
News For AGN;TEVA;NVS From The Last 14 Days
Check below for free stories on AGN;TEVA;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 28, 2014
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
07:21 EDTTEVATeva recalls batch of generic Parkinson's drug in U.S., Globes reports
Subscribe for More Information
August 27, 2014
13:33 EDTAGNValeant, Pershing suit against Allergan expedited, WSJ says
After a hearing on Wednesday morning in Delaware Chancery Court, a judge has expedited a lawsuit from Valeant (VRX) and Pershing Square's William Ackman against Allergan (AGN), says the Wall Street Journal. Last week Valeant and Ackman sued Allergan to quickly schedule a special meeting to decide on the fate of Allergan's board members, added the Wall Street Journal. Reference Link
August 26, 2014
20:04 EDTAGNAllergan requests block to Ackman, Valeant votes, announces Special Meeting date
Subscribe for More Information
16:45 EDTAGNAllergan schedules special meeting on takeover for December 18, WSJ says
Subscribe for More Information
August 22, 2014
19:02 EDTAGNAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTAGNPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTAGNValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTAGNJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTAGNJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
15:16 EDTTEVADEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
August 20, 2014
17:59 EDTAGNAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTAGNAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
10:53 EDTAGNAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTAGNAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use